WASHINGTON, DC — Ben Wakana, the executive director of Patients For Affordable Drugs Now, issued the following statement in response to the Trump administration’s four drug pricing executive orders. The organization previously ran a nearly $1 million campaign in support of one of those orders, HHS’s proposed International Pricing Index.

“The administration’s decision to bring drug prices in Medicare Part B more in line with what other wealthy nations pay would be a positive step if implemented. Abandoning the rule at this stage would be a capitulation to drug corporations.

“Big Pharma has had decades to self-regulate and lower list prices. Not only has it failed to do so, drug corporations continue to raise drug prices –– even in the middle of a pandemic.

“While the Trump administration’s original plan to use international reference pricing was limited — as it would only impact Medicare beneficiaries in half the country, who take certain medications, for a limited amount of time — it would help alleviate the pain of skyrocketing drug prices, and we strongly encourage the rule to be finalized.

“The goal of ridding our system of secret deals between drug companies and pharmacy benefit managers is laudable. We look forward to seeing more details of how this plan will work. In addition, we support the administration’s plans to allow importation from Canada and lower the cost of insulin and EpiPens for patients who rely on Federally Qualified Health Centers.

“We are hopeful the administration moves ahead with these executive orders and look forward to additional details.”